SCHEMBL9955853

SCHEMBL9955853

COC(=O)c1cc(Br)c2nc(Br)sc2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.45
KDM4E B2RXH2 3/20 0.45
PIK3CA P42336 1/20 0.45
PIK3CB P42338 1/20 0.45
PIK3CG P48736 1/20 0.45
PI4KB Q9UBF8 1/20 0.45
HDAC1 Q13547 1/20 0.44
SMN1; SMN2 Q16637 5/20 0.43
KMT2A Q03164 5/20 0.43
MEN1 O00255 4/20 0.43
LMNA P02545 3/20 0.43
GAA P10253 3/20 0.43
HTT P42858 3/20 0.43
TNF P01375 2/20 0.43
MAPT P10636 2/20 0.43
HPGD P15428 2/20 0.43
MCL1 Q07820 2/20 0.43
NOD1 Q9Y239 2/20 0.43
NOD2 Q9HC29 1/20 0.43
NPC1 O15118 6/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29644660 1.00 ALDH1A1 (0.45) ALDH1A1KDM4EPIK3CAPIK3CBPIK3CG
SCHEMBL20839867 0.88 HDAC1 (0.43) ALDH1A1KDM4EPIK3CAPIK3CBPIK3CG
SCHEMBL31309405 0.88 NPC1 (0.48) ALDH1A1KDM4EPIK3CAPIK3CBPIK3CG
SCHEMBL2920222 0.87 CYP2C9 (0.46) ALDH1A1KDM4EPIK3CAPIK3CBPIK3CG
SCHEMBL9957845 0.86 PIK3CA (0.44) ALDH1A1KDM4EPIK3CAPIK3CBPIK3CG
SCHEMBL31341995 0.85 PIK3CA (0.43) ALDH1A1KDM4EPIK3CAPIK3CBPIK3CG
SCHEMBL2275524 0.85 SMN1; SMN2 (0.55) ALDH1A1KDM4EPIK3CAPIK3CBPIK3CG
SCHEMBL20031462 0.85 ALDH1A1 (0.46) ALDH1A1KDM4EPIK3CAPIK3CBPIK3CG
SCHEMBL21195563 0.84 NPC1 (0.42) ALDH1A1KDM4EPIK3CAPIK3CBPIK3CG
SCHEMBL23730805 0.82 NPC1 (0.44) ALDH1A1KDM4EPIK3CAPIK3CBPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2655370-A1 COMPOSITIONS AND METHODS FOR MODULATING FXR IRM LLC (BM) 2013-10-30 EP claimed
WO-2012087519-A1 COMPOSITIONS AND METHODS FOR MODULATING FXR IRM LLC (BM) 2012-06-28 WO claimed
EP-2655370-B1 COMPOSITIONS AND METHODS FOR MODULATING FXR NOVARTIS AG (CH) 2017-08-02 EP disclosed
EP-2655370-B1 COMPOSITIONS AND METHODS FOR MODULATING FXR NOVARTIS AG (CH) 2017-08-02 EP disclosed
US-20150366856-A1 COMPOUNDS AND METHODS FOR MODULATING FXR NOVARTIS AG (CH) 2015-12-24 US disclosed
US-20150366856-A1 COMPOUNDS AND METHODS FOR MODULATING FXR NOVARTIS AG (CH) 2015-12-24 US disclosed
US-20150366856-A1 COMPOUNDS AND METHODS FOR MODULATING FXR NOVARTIS AG (CH) 2015-12-24 US disclosed
US-9150568-B2 Compositions and methods for modulating FXR NOVARTIS AG (CH) 2015-10-06 US disclosed
US-9150568-B2 Compositions and methods for modulating FXR NOVARTIS AG (CH) 2015-10-06 US disclosed
US-20130331349-A1 COMPOSITIONS AND METHODS FOR MODULATING FXR IRM LLC (BM) 2013-12-12 US disclosed
EP-2655370-A1 COMPOSITIONS AND METHODS FOR MODULATING FXR IRM LLC (BM) 2013-10-30 EP disclosed
WO-2012087519-A1 COMPOSITIONS AND METHODS FOR MODULATING FXR IRM LLC (BM) 2012-06-28 WO disclosed
WO-2012087519-A1 COMPOSITIONS AND METHODS FOR MODULATING FXR IRM LLC (BM) 2012-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150366856-A1 COMPOUNDS AND METHODS FOR MODULATING FXR NR1H4, SLC10A1, FXR1 ALDH1A1 2611/4885KDM4E 3613/4885PIK3CA 1597/4885
US-20130331349-A1 COMPOSITIONS AND METHODS FOR MODULATING FXR NR1H4, SLC10A1, FXR1 ALDH1A1 2951/4885KDM4E 3775/4885PIK3CA 1185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.